Evogene Ltd. recently announced an expanded phase of its collaboration with Google Cloud. Under this new phase, the collaboration will focus on developing and integrating advanced AI Agents into Evogene’s ChemPass AI platform, its proprietary engine for small-molecule discovery and optimization, using Google Cloud’s Vertex AI platform. The goal is to increase the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development.

This announcement marks the second major milestone in the partnership between Evogene and Google Cloud, following the successful collaboration announced in October 2024. The initial phase focused on building a generative AI foundation model that now serves as a core component of ChemPass AI. This powerful capability drove Evogene’s recent collaborations, and the addition of our new agent technology positions the company to broaden its offering and accelerate future partnerships.

AI agents represent a new generation of artificial intelligence systems that can independently plan, reason, and execute complex, multi-step scientific workflows. When integrated into ChemPass AI, these agents are designed to automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design–make–test–analyze cycles, and improve the accuracy and success rate of designing small-molecule based products.

These capabilities directly support Evogene’s core objective: identifying high-quality small molecules that meet multiple, stringent criteria required to become commercially viable product candidates. The expanded collaboration is expected to further strengthen Evogene’s position as a leader in next-generation molecular design for both pharmaceutical and agricultural markets.

Boaz Maoz, Managing Director, Google Cloud Israel, commented “This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene’s role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries.”

Ofer Haviv, President and CEO of Evogene, said “Evogene is pleased to further expand its collaboration with Google Cloud. The integration of AI agents into ChemPass AI is expected to improve our speed, cost structure, and ability to run multiple discovery programs in parallel. We are also excited about the potential to make parts of our real-world innovation tools globally accessible through Google Cloud Marketplace. This collaboration marks for us a shift from AI models to autonomous discovery, as ChemPass AI enters a new phase of scale and execution.”

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach Real-World Innovation. Learn more at: www.evogene.com.